On April 7, 2020, Guizhou Tian'an Pharmaceutical Co., Ltd. and its parent company Boya Biotech Co., Ltd. jointly announced that Guizhou Tian'an Pharmaceutical's glimepiride tablets (2mg dosage) had passed the consistency evaluation for generic drug quality and efficacy. The company received the “Supplemental Application Approval Document” issued by the National Medical Products Administration.

Warm congratulations to Guizhou Tian'an Pharmaceutical on achieving compliance for another generic drug consistency evaluation product following its metformin hydrochloride tablets. We also congratulate DiQi Pharmaceuticals Co., Ltd on successfully completing two pharmaceutical research projects commissioned by Guizhou Tian'an Pharmaceutical, both of which have passed the generic drug consistency evaluation!

We extend our gratitude to all partners of DiQi Pharmaceuticals Co., Ltd for their enduring trust and support, and we thank every member of the DiQi team for their dedicated efforts!